Almirall

ALM · BME · Spain

Public Market Listing

ALMBME

BME primary exchange listing

Live quotes, historical charts, and market capitalization for Almirall are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(5 total)
5Total Assets
3Approved
1Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Approved
Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptorSmall molecule
Chronic Obstructive Pulmonary Disease
lebrikizumab(Ebglyss)
Approved
IL-13Monoclonal antibody
Atopic Dermatitis
Approved
IL-23 p19Monoclonal antibody
Psoriatic ArthritisPsoriasis
US approval withdrawn
5-HT1B/1D receptorSmall molecule
Migraine
Phase 3
Nrf2 pathway (fumaric acid ester)Small molecule
Psoriasis

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
April 2027 (1)
lebrikizumab · EbglyssPhase 3Dermatitis, Atopic, Eczema
Est. primary completion 2027-04-25 · NCT06526182 · CT.gov ↗
What to watch
May 2027 (1)
lebrikizumab · EbglyssPhase 3Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Est. primary completion 2027-05 · NCT06338995 · CT.gov ↗
What to watch
December 2027 (1)
lebrikizumab · EbglyssPhase 3Atopic Dermatitis, Eczema
Est. primary completion 2027-12 · NCT05735483 · CT.gov ↗
What to watch
2028 (3)
February 2028 (1)
lebrikizumab · EbglyssPhase 3Atopic Dermatitis
Est. primary completion 2028-02 · NCT07873801 · CT.gov ↗
What to watch
August 2028 (1)
lebrikizumab · EbglyssPhase 3Nummular Eczema
Est. primary completion 2028-08 · NCT07542483 · CT.gov ↗
What to watch
December 2028 (1)
tildrakizumab · IlumyaPhase 3Psoriatic Arthritis
Est. primary completion 2028-12 · NCT04991116 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 October 2026FDA action datetildrakizumabILUMYA psoriatic arthritis FDA action date October 29, 2026
US, FDA · Sun Pharmaceutical Industries · Source ↗
29 October 2026ApprovaltildrakizumabFDA approves ILUMYA in active psoriatic arthritis
US, FDA · Source ↗
9 June 2026ApprovallebrikizumabFDA approves EBGLYSS once-every-eight-weeks maintenance dosing
US, FDA · Source ↗
16 March 2026Filing acceptedtildrakizumabFDA accepts ILUMYA sBLA for psoriatic arthritis
US, FDA · Sun Pharmaceutical Industries · Source ↗
21 July 2025Topline resulttildrakizumabINSPIRE-1 and INSPIRE-2 Phase 3 met primary endpoint
Sun Pharmaceutical Industries · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-H1$703M—$405M—report ↗